Mozafari P, Ibrahim SA, Pawar AA, Ali ZIO, Nair AS. Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk during Extended Ocrelizumab Therapy in Multiple Sclerosis. JR [Internet]. 2026 Jul. 13 [cited 2026 Jul. 13];4(2):57-69. Available from: https://journals.4science.ge/index.php/jr/article/view/4978